Demand for drug discovery services is growing again according to Domainex, who predicted that we will see greater pharmaceutical industry reliance on specialist CROs going forward.

CRO Quintiles says biomarkers give insight into cancer drug candidates’ efficacy earlier in the development process, reducing trial costs and duration.

Quintiles’ Jay Norman tells Outsourcing-pharma that data sharing and patient and payer concerns will drive drug industry competition and clinical development decisions accord to new research.

The role of the pharma industry in supporting the COE anti-counterfeiting treaty, which aims to criminalise activities, “cannot be underestimated”, according to a directorate member.

Increased focus on post-market safety and value has resulted in CROs handling more Phase IV work, according to a PharmaNet EVP, and this trend may continue as regulators seek real world evidence.

Russia, the Ukraine and Belarus have emerged as destinations for clinical studies and now offer “enormous” potential according to US-based CRO ClinStar.

Aluminium foil as a packaging solution is marking its centenary in 2010. Stefan Glimm, executive director of the European Aluminium Foil Association (EAFA), reflects on how this packing mainstay continues to build on its ability to provide the highest barrier protection properties while adapting to the needs of the new millennium.

Recipharm CEO Thomas Eldered reflects on RecipharmCobra Biologics (RCB) launch, telling Outsourcing-pharma that US is key market.

Liquent and Take Solutions say their new partnership provides pharmaceutical firms with an efficient, cost effective outsourced solution for regulatory publication and submissions.

CEO Steffen Mittwich updates in-PharmaTechnologist on Atacama Labs' pneumatic dry granulation (PDG) API processing tech, its deal with German CMO Excella and future development plans.